RNA sequencing of tumor tissue that looks for transcriptome abnormalities relevant to treatment.
Consented intake · your records travel with you · nothing moves without your sign-off
The NextGen Oncology Panther test maps and analyzes RNA variants from tumor tissue. It is designed to uncover transcriptome abnormalities that may inform treatment. Patients and their care teams can use these results to better understand what the cancer is expressing, adding context beyond DNA findings when weighing treatment options.
The fastest way to know what you'll pay: check your coverage with your plan. Below is what we know about how NextGen Oncology Panther test handles billing.
We don't have confirmed insurance details for NextGen Oncology Panther test yet. Start a coverage check with your plan, or contact the provider directly.
Answers grounded in NextGen's details here. Educational only; your oncologist directs treatment.
Powered by Navis on opencancer.ai
Other providers in similar categories.
Gather distinctive biomarkers that can guide treatment and monitor disease progression
FoundationOne CDx is an FDA-approved comprehensive genomic profiling test that analyzes 324 genes to identify clinically relevant genomic alterations.
Tempus xT is a comprehensive genomic profiling test combining DNA and RNA sequencing to identify actionable mutations.
Matches your tumor's biomarkers to the therapies most likely to work for you — mapping your molecular profile to targeted and approved options.
This page is general information. Upload your records for analysis specific to YOUR diagnosis.